Manish Upadhyay, MD
Endocrinology, Diabetes & Metabolism · Roseville, CANPI 1962432039
Payments from drug & device makers
Across 291 payments — averaging $14.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Amgen$478
- Lilly USA, LLC$412
- Sanofi-aventis U.S. LLC$334
- AstraZeneca$175
- Neuronetics, Inc.$168
- plus $1K from 22 others
What the payments were for
- Speaking & faculty fees$1052%
- Food & beverage$4,16796%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 167 | $1,659 |
| Amgen(2 entities) | 28 | $478 |
| Lilly USA, LLC | 22 | $412 |
| Sanofi-aventis U.S. LLC | 15 | $334 |
| AstraZeneca(2 entities) | 7 | $175 |
| Neuronetics, Inc. | 3 | $168 |
| Boehringer Ingelheim | 7 | $166 |
| Radius Health, Inc. | 6 | $143 |
| AbbVie | 7 | $132 |
| Abbott | 5 | $118 |
| BETA Bionics, Inc. | 3 | $81 |
| Zealand Pharma US, Inc. | 3 | $52 |
| Ascendis Pharma Endocrinology Inc | 2 | $50 |
| Dexcom, Inc. | 1 | $41 |
| Ionis Pharmaceuticals, Inc. | 1 | $37 |
| Sequel Med Tech, LLC | 1 | $36 |
| Mannkind Corporation | 2 | $32 |
| Bigfoot Biomedical Inc | 1 | $30 |
| Ascensia Diabetes Care US Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Tolmar, Inc. | 1 | $25 |
| Halozyme Inc | 1 | $24 |
| Antares Pharma, Inc. | 1 | $24 |
| Bayer | 1 | $21 |
| IBSA Pharma Inc. | 1 | $18 |
| Cequr Corporation | 1 | $16 |
| Tandem Diabetes Care, Inc. | 1 | $14 |
| Medtronic | 1 | $12 |
How this compares
$4,347 in reported general payments places this provider in the 65th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 326 | $416,426 |
| JardianceEmpagliflozin | 413 | $399,549 |
| MounjaroTirzepatide | 245 | $330,081 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 78 | $138,382 |
| Tresiba Flextouch U-100Insulin Degludec | 160 | $112,724 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 106 | $69,198 |
| Tresiba Flextouch U-200Insulin Degludec | 50 | $60,887 |
| GlyxambiEmpagliflozin/Linagliptin | 45 | $49,446 |
| TrulicityDulaglutide | 33 | $42,822 |
| FarxigaDapagliflozin Propanediol | 45 | $40,611 |
| Humalog Kwikpen U-100Insulin Lispro | 159 | $38,085 |
| Teriparatide | 16 | $35,389 |
| RybelsusSemaglutide | 23 | $34,895 |
| SynthroidLevothyroxine Sodium | 327 | $28,193 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $20,373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $166 | $467,289494 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,659 | $454,504366 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $412 | $393,899313 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $334 | $141,114102 claims |
| AstraZenecaFarxiga | $175 | $40,61145 claims |
| AbbVieSynthroid | $132 | $28,193327 claims |
| IBSA Pharma Inc.Tirosint | $18 | $9,88425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Roseville
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
- Shlomo MelmedLos Angeles$3.3M
- Leila ChaychiSan Carlos$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.